vs
艾伯维（ABBV）与COMMUNITY HEALTH SYSTEMS INC（CYH）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是COMMUNITY HEALTH SYSTEMS INC的5.4倍（$16.6B vs $3.1B）。艾伯维净利率更高（10.9% vs 3.5%，领先7.4%）。艾伯维同比增速更快（10.0% vs -4.8%）。艾伯维自由现金流更多（$4.9B vs $172.0M）。过去两年艾伯维的营收复合增速更高（16.2% vs -0.5%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
社区卫生系统公司总部位于美国田纳西州富兰克林，是财富500强企业。按急症护理机构数量计算，该公司曾是美国最大的综合医院医疗服务提供商。2014年它旗下有约200家医院，到2021年机构数量缩减至约85家。
ABBV vs CYH — 直观对比
营收规模更大
ABBV
是对方的5.4倍
$3.1B
营收增速更快
ABBV
高出14.9%
-4.8%
净利率更高
ABBV
高出7.4%
3.5%
自由现金流更多
ABBV
多$4.7B
$172.0M
两年增速更快
ABBV
近两年复合增速
-0.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $3.1B |
| 净利润 | $1.8B | $110.0M |
| 毛利率 | 72.6% | 85.6% |
| 营业利润率 | 27.3% | 14.5% |
| 净利率 | 10.9% | 3.5% |
| 营收同比 | 10.0% | -4.8% |
| 净利润同比 | 8354.5% | 254.9% |
| 每股收益（稀释后） | $1.02 | $0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVCYH
| Q4 25 | $16.6B | $3.1B | ||
| Q3 25 | $15.8B | $3.1B | ||
| Q2 25 | $15.4B | $3.1B | ||
| Q1 25 | $13.3B | $3.2B | ||
| Q4 24 | $15.1B | $3.3B | ||
| Q3 24 | $14.5B | $3.1B | ||
| Q2 24 | $14.5B | $3.1B | ||
| Q1 24 | $12.3B | $3.1B |
净利润ABBVCYH
| Q4 25 | $1.8B | $110.0M | ||
| Q3 25 | $186.0M | $130.0M | ||
| Q2 25 | $938.0M | $282.0M | ||
| Q1 25 | $1.3B | $-13.0M | ||
| Q4 24 | $-22.0M | $-71.0M | ||
| Q3 24 | $1.6B | $-391.0M | ||
| Q2 24 | $1.4B | $-13.0M | ||
| Q1 24 | $1.4B | $-41.0M |
毛利率ABBVCYH
| Q4 25 | 72.6% | 85.6% | ||
| Q3 25 | 66.4% | 85.1% | ||
| Q2 25 | 71.8% | 85.0% | ||
| Q1 25 | 70.0% | 84.5% | ||
| Q4 24 | 70.9% | 84.5% | ||
| Q3 24 | 70.9% | 84.8% | ||
| Q2 24 | 70.9% | 84.6% | ||
| Q1 24 | 66.7% | 84.5% |
营业利润率ABBVCYH
| Q4 25 | 27.3% | 14.5% | ||
| Q3 25 | 12.1% | 7.9% | ||
| Q2 25 | 31.7% | 16.3% | ||
| Q1 25 | 28.0% | 9.0% | ||
| Q4 24 | -9.9% | 8.5% | ||
| Q3 24 | 26.5% | -6.6% | ||
| Q2 24 | 27.6% | 7.6% | ||
| Q1 24 | 22.7% | 7.4% |
净利率ABBVCYH
| Q4 25 | 10.9% | 3.5% | ||
| Q3 25 | 1.2% | 4.2% | ||
| Q2 25 | 6.1% | 9.0% | ||
| Q1 25 | 9.6% | -0.4% | ||
| Q4 24 | -0.1% | -2.2% | ||
| Q3 24 | 10.8% | -12.7% | ||
| Q2 24 | 9.5% | -0.4% | ||
| Q1 24 | 11.1% | -1.3% |
每股收益（稀释后）ABBVCYH
| Q4 25 | $1.02 | $0.82 | ||
| Q3 25 | $0.10 | $0.96 | ||
| Q2 25 | $0.52 | $2.09 | ||
| Q1 25 | $0.72 | $-0.10 | ||
| Q4 24 | $-0.03 | $-0.53 | ||
| Q3 24 | $0.88 | $-2.95 | ||
| Q2 24 | $0.77 | $-0.10 | ||
| Q1 24 | $0.77 | $-0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $260.0M |
| 总债务越低越好 | $58.9B | $10.4B |
| 股东权益账面价值 | $-3.3B | $-1.4B |
| 总资产 | $134.0B | $13.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABBVCYH
| Q4 25 | $5.3B | $260.0M | ||
| Q3 25 | $5.7B | $123.0M | ||
| Q2 25 | $6.5B | $456.0M | ||
| Q1 25 | $5.2B | $431.0M | ||
| Q4 24 | $5.6B | $37.0M | ||
| Q3 24 | $7.3B | $33.0M | ||
| Q2 24 | $13.2B | $39.0M | ||
| Q1 24 | $18.1B | $48.0M |
总债务ABBVCYH
| Q4 25 | $58.9B | $10.4B | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | $11.5B | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVCYH
| Q4 25 | $-3.3B | $-1.4B | ||
| Q3 25 | $-2.6B | $-1.5B | ||
| Q2 25 | $-183.0M | $-1.6B | ||
| Q1 25 | $1.4B | $-1.9B | ||
| Q4 24 | $3.3B | $-1.9B | ||
| Q3 24 | $6.0B | $-1.8B | ||
| Q2 24 | $6.8B | $-1.4B | ||
| Q1 24 | $8.0B | $-1.4B |
总资产ABBVCYH
| Q4 25 | $134.0B | $13.2B | ||
| Q3 25 | $133.9B | $13.2B | ||
| Q2 25 | $137.2B | $13.6B | ||
| Q1 25 | $136.2B | $13.9B | ||
| Q4 24 | $135.2B | $14.1B | ||
| Q3 24 | $143.4B | $13.9B | ||
| Q2 24 | $141.9B | $14.4B | ||
| Q1 24 | $148.9B | $14.4B |
负债/权益比ABBVCYH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $266.0M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $172.0M |
| 自由现金流率自由现金流/营收 | 29.4% | 5.5% |
| 资本支出强度资本支出/营收 | 2.0% | 3.0% |
| 现金转化率经营现金流/净利润 | 2.87× | 2.42× |
| 过去12个月自由现金流最近4个季度 | $17.8B | $208.0M |
8季度趋势，按日历期对齐
经营现金流ABBVCYH
| Q4 25 | $5.2B | $266.0M | ||
| Q3 25 | $7.0B | $69.0M | ||
| Q2 25 | $5.2B | $88.0M | ||
| Q1 25 | $1.6B | $120.0M | ||
| Q4 24 | $7.0B | $216.0M | ||
| Q3 24 | $5.4B | $67.0M | ||
| Q2 24 | $2.3B | $101.0M | ||
| Q1 24 | $4.0B | $96.0M |
自由现金流ABBVCYH
| Q4 25 | $4.9B | $172.0M | ||
| Q3 25 | $6.6B | $4.0M | ||
| Q2 25 | $4.9B | $-3.0M | ||
| Q1 25 | $1.4B | $35.0M | ||
| Q4 24 | $6.8B | $107.0M | ||
| Q3 24 | $5.2B | $-3.0M | ||
| Q2 24 | $2.0B | $13.0M | ||
| Q1 24 | $3.8B | $3.0M |
自由现金流率ABBVCYH
| Q4 25 | 29.4% | 5.5% | ||
| Q3 25 | 42.1% | 0.1% | ||
| Q2 25 | 31.7% | -0.1% | ||
| Q1 25 | 10.5% | 1.1% | ||
| Q4 24 | 44.7% | 3.3% | ||
| Q3 24 | 35.9% | -0.1% | ||
| Q2 24 | 14.0% | 0.4% | ||
| Q1 24 | 31.3% | 0.1% |
资本支出强度ABBVCYH
| Q4 25 | 2.0% | 3.0% | ||
| Q3 25 | 2.4% | 2.1% | ||
| Q2 25 | 1.7% | 2.9% | ||
| Q1 25 | 1.8% | 2.7% | ||
| Q4 24 | 1.9% | 3.3% | ||
| Q3 24 | 1.7% | 2.3% | ||
| Q2 24 | 1.7% | 2.8% | ||
| Q1 24 | 1.6% | 3.0% |
现金转化率ABBVCYH
| Q4 25 | 2.87× | 2.42× | ||
| Q3 25 | 37.76× | 0.53× | ||
| Q2 25 | 5.49× | 0.31× | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
CYH
| Managed Care And Other Third Party Payors | $1.5B | 49% |
| Medicare Managed Care | $570.0M | 18% |
| Medicare | $512.0M | 16% |
| Medicaid | $464.0M | 15% |
| Self Pay Revenue | $34.0M | 1% |
